Evidence map›Paper›PMID 38643010›Full record

ArticleBMJ open2024

Patient preferences in genetic newborn screening for rare diseases: study protocol.

Sylvia Martin, Emanuele Angolini, Jennifer Audi, Enrico Bertini, Lucia Pia Bruno, Joshua Coulter, Alessandra Ferlini, Fernanda Fortunato, Vera Frankova, Nicolas Garnier and 13 more

Open access · goldAbstract read
In one paragraph

Article in BMJ open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 12 institutions in 9 countries.

Sylvia MartinCenter for Research and Bioethics, Uppsala Universitet, Uppsala, Sweden sylvia.martin@crb.uu.se.ORCID 0000-0002-3706-7669
Emanuele AngoliniResearch Unit of Neuromuscular and Neurodegenerative Disease, Ospedale Pediatrico Bambino Gesù IRCCS, Roma, Lazio, Italy.
Jennifer AudiTakeda Pharmaceuticals International AG, Opfikon, Zürich, Switzerland.
Enrico BertiniResearch Unit of Neuromuscular and Neurodegenerative Disease, Ospedale Pediatrico Bambino Gesù IRCCS, Roma, Lazio, Italy.
Lucia Pia BrunoMedical Genetics, University of Siena, Siena, Italy.
Joshua CoulterPfizer Inc, New York, New York, USA.
Alessandra FerliniMedical Genetics Unit, Department of Medical Sciences, University of Ferrara, Ferrara, Italy.
Fernanda FortunatoMedical Genetics Unit, Department of Medical Sciences, University of Ferrara, Ferrara, Italy.
Vera FrankovaInstitute for Medical Humanities, First Faculty of Medicine, Charles University, Prague, Czech Republic.
Nicolas GarnierPfizer Inc, New York, New York, USA.
Åsa GraumanCenter for Research and Bioethics, Uppsala Universitet, Uppsala, Sweden.
Edith GrossEURORDIS, Paris, Ile-de-France, France.
Brett HauberPfizer Inc, New York, New York, USA.
Mats HanssonCenter for Research and Bioethics, Uppsala Universitet, Uppsala, Sweden.
Janbernd KirschnerDepartment of Neuropediatrics and Muscle Disorders, Medical Center, University of Freiburg, Faculty of Medicine, Freiburg, Germany.ORCID 0000-0003-1618-7386
Ferdinand KnielingErlangen University Hospital, Erlangen, Bayern, Germany.
Gergana KyosovksaBulgarian Association for Personalised Medicine, Sofia, Bulgaria.
Silvia OttombrinoResearch Unit of Neuromuscular and Neurodegenerative Disease, Ospedale Pediatrico Bambino Gesù IRCCS, Roma, Lazio, Italy.
Antonio NovelliResearch Unit of Neuromuscular and Neurodegenerative Disease, Ospedale Pediatrico Bambino Gesù IRCCS, Roma, Lazio, Italy.
Roman RamingErlangen University Hospital, Erlangen, Bayern, Germany.
Stefaan SansenSanofi-Aventis SA, Diegem, Belgium.
Christina SaierDepartment of Neuropediatrics and Muscle Disorders, Faculty of Medicine, Freiburg, Germany.
Jorien VeldwijkErasmus Universiteit Rotterdam, Rotterdam, Netherlands.
Bambino Gesù Children's Hospital · ITPfizer (United States) · USUppsala University · SEUniversitätsklinikum Erlangen · DEUniversity of Ferrara · ITCharles University · CZErasmus University Rotterdam · NLEuropean Organisation for Rare Diseases · FRSanofi (Belgium) · BETakeda (Switzerland) · CHUniversity of Freiburg · DEUniversity of Siena · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionRare diseases (RDs) collectively impact over 30 million people in Europe. Most individual conditions have a low prevalence which has resulted in a lack of research and expertise in this field, especially regarding genetic newborn screening (gNBS). There is increasing recognition of the importance of incorporating patients' needs and general public perspectives into the shared decision-making process regarding gNBS. This study is part of the Innovative Medicine Initiative project Screen4Care which aims at shortening the diagnostic journey for RDs by accelerating diagnosis for patients living with RDs through gNBS and the use of digital technologies, such as artificial intelligence and machine learning. Our objective will be to assess expecting parent's perspectives, attitudes and preferences regarding gNBS for RDs in Italy and Germany. METHODS AND ANALYSIS: A mixed method approach will assess perspectives, attitudes and preferences of (1) expecting parents seeking genetic consultation and (2) 'healthy' expecting parents from the general population in two countries (Germany and Italy). Focus groups and interviews using the nominal group technique and ranking exercises will be performed (qualitative phase). The results will inform the treatment of attributes to be assessed via a survey and a discrete choice experiment (DCE). The total recruitment sample will be 2084 participants (approximatively 1000 participants in each country for the online survey). A combination of thematic qualitative and logit-based quantitative approaches will be used to analyse the results of the study. ETHICS AND DISSEMINATION: This study has been approved by the Erlangen University Ethics Committee (22-246_1-B), the Freiburg University Ethics Committee (23-1005 S1-AV) and clinical centres in Italy (University of FerraraCE: 357/2023/Oss/AOUFe and Hospedale Bambino Gesu: No.2997 of 2 November 2023, Prot. No. _902) and approved for data storage and handling at the Uppsala University (2022-05806-01). The dissemination of the results will be ensured via scientific journal publication (open access).

Indexed as

Neonatal ScreeningPatient PreferenceArtificial IntelligenceFocus GroupsHumansInfant, NewbornRare DiseasesGENETICSPatient-Centered CarePatient ParticipationPatient Reported Outcome MeasuresQUALITATIVE RESEARCH

Identifiers

PMID38643010
PMCPMC11056621
OpenAlexW4394980182

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.